论文部分内容阅读
用肝细胞生长刺激素(HSS)治疗慢性乙型肝炎肝硬变56例。通过积分法评价两组治疗前后临床症状和肝功能的变化。治疗组14例治疗前后测定血清微量蛋白。结果显示:临床症状治疗前后平均积分。治疗组17.6±6.9和10.1±5.7,对照组18.3±6.5和16.6±7.4.肝功能.临床改善率,治疗和对照组分别为67.7％和44.0％,两组有显著差异(P<0.05)。治疗前后血清前白蛋白为1.74±0.60和2.49±0.90g/L(P<0.01),触珠白蛋白治疗后回升率42.8％,提示HSS确有提高慢性乙型肝炎肝硬变患者的肝脏白蛋白储备功能,增强机体细胞免疫的作用。
Treating 56 cases of chronic hepatitis B cirrhosis with hepatocyte growth stimulating hormone (HSS). Integral method was used to evaluate the changes of clinical symptoms and liver function before and after treatment. The treatment group of 14 patients before and after treatment serum trace protein. The results showed that: clinical symptoms before and after treatment, the average score. 17.6 ± 6.9 and 10.1 ± 5.7 in the treatment group and 18.3 ± 6.5 and 16.6 ± 7.4 in the control group, and the clinical improvement rate of the liver function was 67.7% and 44.0% in the treatment group and the control group respectively, with significant difference between the two groups (P <0.05). Pre-and post-treatment serum albumin was 1.74 ± 0.60 and 2.49 ± 0.90g / L (P <0.01), and the response rate of haptoglobin was 42.8%, suggesting that HSS did improve liver whiteness in patients with chronic hepatitis B cirrhosis Protein reserves, enhance the role of cellular immunity.